Neutralization Properties of Simian Immunodeficiency Viruses Infecting Chimpanzees and Gorillas
ABSTRACT Broadly cross-reactive neutralizing antibodies (bNabs) represent powerful tools to combat human immunodeficiency virus type 1 (HIV-1) infection. Here, we examined whether HIV-1-specific bNabs are capable of cross-neutralizing distantly related simian immunodeficiency viruses (SIVs) infectin...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
American Society for Microbiology
2015
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/46821e94c4f84dc3b70247c0404d431a |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:46821e94c4f84dc3b70247c0404d431a |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:46821e94c4f84dc3b70247c0404d431a2021-11-15T15:41:33ZNeutralization Properties of Simian Immunodeficiency Viruses Infecting Chimpanzees and Gorillas10.1128/mBio.00296-152150-7511https://doaj.org/article/46821e94c4f84dc3b70247c0404d431a2015-05-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mBio.00296-15https://doaj.org/toc/2150-7511ABSTRACT Broadly cross-reactive neutralizing antibodies (bNabs) represent powerful tools to combat human immunodeficiency virus type 1 (HIV-1) infection. Here, we examined whether HIV-1-specific bNabs are capable of cross-neutralizing distantly related simian immunodeficiency viruses (SIVs) infecting central (Pan troglodytes troglodytes) (SIVcpzPtt) and eastern (Pan troglodytes schweinfurthii) (SIVcpzPts) chimpanzees (n = 11) as well as western gorillas (Gorilla gorilla gorilla) (SIVgor) (n = 1). We found that bNabs directed against the CD4 binding site (n = 10), peptidoglycans at the base of variable loop 3 (V3) (n = 5), and epitopes at the interface of surface (gp120) and membrane-bound (gp41) envelope glycoproteins (n = 5) failed to neutralize SIVcpz and SIVgor strains. In addition, apex V2-directed bNabs (n = 3) as well as llama-derived (heavy chain only) antibodies (n = 6) recognizing both the CD4 binding site and gp41 epitopes were either completely inactive or neutralized only a fraction of SIVcpzPtt strains. In contrast, one antibody targeting the membrane-proximal external region (MPER) of gp41 (10E8), functional CD4 and CCR5 receptor mimetics (eCD4-Ig, eCD4-Igmim2, CD4-218.3-E51, and CD4-218.3-E51-mim2), as well as mono- and bispecific anti-human CD4 (iMab and LM52) and CCR5 (PRO140, PRO140-10E8) receptor antibodies neutralized >90% of SIVcpz and SIVgor strains with low-nanomolar (0.13 to 8.4 nM) potency. Importantly, the latter antibodies blocked virus entry not only in TZM-bl cells but also in Cf2Th cells expressing chimpanzee CD4 and CCR5 and neutralized SIVcpz in chimpanzee CD4+ T cells, with 50% inhibitory concentrations (IC50s) ranging from 3.6 to 40.5 nM. These findings provide new insight into the protective capacity of anti-HIV-1 bNabs and identify candidates for further development to combat SIVcpz infection. IMPORTANCE SIVcpz is widespread in wild-living chimpanzees and can cause AIDS-like immunopathology and clinical disease. HIV-1 infection of humans can be controlled by antiretroviral therapy; however, treatment of wild-living African apes with current drug regimens is not feasible. Nonetheless, it may be possible to curb the spread of SIVcpz in select ape communities using vectored immunoprophylaxis and/or therapy. Here, we show that antibodies and antibody-like inhibitors developed to combat HIV-1 infection in humans are capable of neutralizing genetically diverse SIVcpz and SIVgor strains with considerable breadth and potency, including in primary chimpanzee CD4+ T cells. These reagents provide an important first step toward translating intervention strategies currently developed to treat and prevent AIDS in humans to SIV-infected apes.Hannah J. BarbianJulie M. DeckerFrederic Bibollet-RucheRachel P. GalimidiAnthony P. WestGerald H. LearnNicholas F. ParrishShilpa S. IyerYingying LiCraig S. PaceRuijiang SongYaoxing HuangThomas N. DennyHugo MouquetLoic MartinPriyamvada AcharyaBaoshan ZhangPeter D. KwongJohn R. MascolaC. Theo VerripsNika M. StrokappeLucy RuttenLaura E. McCoyRobin A. WeissCorrine S. BrownRaven JacksonGuido SilvestriMark ConnorsDennis R. BurtonGeorge M. ShawMichel C. NussenzweigPamela J. BjorkmanDavid D. HoMichael FarzanBeatrice H. HahnAmerican Society for MicrobiologyarticleMicrobiologyQR1-502ENmBio, Vol 6, Iss 2 (2015) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Microbiology QR1-502 |
| spellingShingle |
Microbiology QR1-502 Hannah J. Barbian Julie M. Decker Frederic Bibollet-Ruche Rachel P. Galimidi Anthony P. West Gerald H. Learn Nicholas F. Parrish Shilpa S. Iyer Yingying Li Craig S. Pace Ruijiang Song Yaoxing Huang Thomas N. Denny Hugo Mouquet Loic Martin Priyamvada Acharya Baoshan Zhang Peter D. Kwong John R. Mascola C. Theo Verrips Nika M. Strokappe Lucy Rutten Laura E. McCoy Robin A. Weiss Corrine S. Brown Raven Jackson Guido Silvestri Mark Connors Dennis R. Burton George M. Shaw Michel C. Nussenzweig Pamela J. Bjorkman David D. Ho Michael Farzan Beatrice H. Hahn Neutralization Properties of Simian Immunodeficiency Viruses Infecting Chimpanzees and Gorillas |
| description |
ABSTRACT Broadly cross-reactive neutralizing antibodies (bNabs) represent powerful tools to combat human immunodeficiency virus type 1 (HIV-1) infection. Here, we examined whether HIV-1-specific bNabs are capable of cross-neutralizing distantly related simian immunodeficiency viruses (SIVs) infecting central (Pan troglodytes troglodytes) (SIVcpzPtt) and eastern (Pan troglodytes schweinfurthii) (SIVcpzPts) chimpanzees (n = 11) as well as western gorillas (Gorilla gorilla gorilla) (SIVgor) (n = 1). We found that bNabs directed against the CD4 binding site (n = 10), peptidoglycans at the base of variable loop 3 (V3) (n = 5), and epitopes at the interface of surface (gp120) and membrane-bound (gp41) envelope glycoproteins (n = 5) failed to neutralize SIVcpz and SIVgor strains. In addition, apex V2-directed bNabs (n = 3) as well as llama-derived (heavy chain only) antibodies (n = 6) recognizing both the CD4 binding site and gp41 epitopes were either completely inactive or neutralized only a fraction of SIVcpzPtt strains. In contrast, one antibody targeting the membrane-proximal external region (MPER) of gp41 (10E8), functional CD4 and CCR5 receptor mimetics (eCD4-Ig, eCD4-Igmim2, CD4-218.3-E51, and CD4-218.3-E51-mim2), as well as mono- and bispecific anti-human CD4 (iMab and LM52) and CCR5 (PRO140, PRO140-10E8) receptor antibodies neutralized >90% of SIVcpz and SIVgor strains with low-nanomolar (0.13 to 8.4 nM) potency. Importantly, the latter antibodies blocked virus entry not only in TZM-bl cells but also in Cf2Th cells expressing chimpanzee CD4 and CCR5 and neutralized SIVcpz in chimpanzee CD4+ T cells, with 50% inhibitory concentrations (IC50s) ranging from 3.6 to 40.5 nM. These findings provide new insight into the protective capacity of anti-HIV-1 bNabs and identify candidates for further development to combat SIVcpz infection. IMPORTANCE SIVcpz is widespread in wild-living chimpanzees and can cause AIDS-like immunopathology and clinical disease. HIV-1 infection of humans can be controlled by antiretroviral therapy; however, treatment of wild-living African apes with current drug regimens is not feasible. Nonetheless, it may be possible to curb the spread of SIVcpz in select ape communities using vectored immunoprophylaxis and/or therapy. Here, we show that antibodies and antibody-like inhibitors developed to combat HIV-1 infection in humans are capable of neutralizing genetically diverse SIVcpz and SIVgor strains with considerable breadth and potency, including in primary chimpanzee CD4+ T cells. These reagents provide an important first step toward translating intervention strategies currently developed to treat and prevent AIDS in humans to SIV-infected apes. |
| format |
article |
| author |
Hannah J. Barbian Julie M. Decker Frederic Bibollet-Ruche Rachel P. Galimidi Anthony P. West Gerald H. Learn Nicholas F. Parrish Shilpa S. Iyer Yingying Li Craig S. Pace Ruijiang Song Yaoxing Huang Thomas N. Denny Hugo Mouquet Loic Martin Priyamvada Acharya Baoshan Zhang Peter D. Kwong John R. Mascola C. Theo Verrips Nika M. Strokappe Lucy Rutten Laura E. McCoy Robin A. Weiss Corrine S. Brown Raven Jackson Guido Silvestri Mark Connors Dennis R. Burton George M. Shaw Michel C. Nussenzweig Pamela J. Bjorkman David D. Ho Michael Farzan Beatrice H. Hahn |
| author_facet |
Hannah J. Barbian Julie M. Decker Frederic Bibollet-Ruche Rachel P. Galimidi Anthony P. West Gerald H. Learn Nicholas F. Parrish Shilpa S. Iyer Yingying Li Craig S. Pace Ruijiang Song Yaoxing Huang Thomas N. Denny Hugo Mouquet Loic Martin Priyamvada Acharya Baoshan Zhang Peter D. Kwong John R. Mascola C. Theo Verrips Nika M. Strokappe Lucy Rutten Laura E. McCoy Robin A. Weiss Corrine S. Brown Raven Jackson Guido Silvestri Mark Connors Dennis R. Burton George M. Shaw Michel C. Nussenzweig Pamela J. Bjorkman David D. Ho Michael Farzan Beatrice H. Hahn |
| author_sort |
Hannah J. Barbian |
| title |
Neutralization Properties of Simian Immunodeficiency Viruses Infecting Chimpanzees and Gorillas |
| title_short |
Neutralization Properties of Simian Immunodeficiency Viruses Infecting Chimpanzees and Gorillas |
| title_full |
Neutralization Properties of Simian Immunodeficiency Viruses Infecting Chimpanzees and Gorillas |
| title_fullStr |
Neutralization Properties of Simian Immunodeficiency Viruses Infecting Chimpanzees and Gorillas |
| title_full_unstemmed |
Neutralization Properties of Simian Immunodeficiency Viruses Infecting Chimpanzees and Gorillas |
| title_sort |
neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas |
| publisher |
American Society for Microbiology |
| publishDate |
2015 |
| url |
https://doaj.org/article/46821e94c4f84dc3b70247c0404d431a |
| work_keys_str_mv |
AT hannahjbarbian neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT juliemdecker neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT fredericbibolletruche neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT rachelpgalimidi neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT anthonypwest neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT geraldhlearn neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT nicholasfparrish neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT shilpasiyer neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT yingyingli neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT craigspace neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT ruijiangsong neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT yaoxinghuang neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT thomasndenny neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT hugomouquet neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT loicmartin neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT priyamvadaacharya neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT baoshanzhang neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT peterdkwong neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT johnrmascola neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT ctheoverrips neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT nikamstrokappe neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT lucyrutten neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT lauraemccoy neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT robinaweiss neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT corrinesbrown neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT ravenjackson neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT guidosilvestri neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT markconnors neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT dennisrburton neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT georgemshaw neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT michelcnussenzweig neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT pamelajbjorkman neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT daviddho neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT michaelfarzan neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas AT beatricehhahn neutralizationpropertiesofsimianimmunodeficiencyvirusesinfectingchimpanzeesandgorillas |
| _version_ |
1718427639637606400 |